Increased medical provider consolidation with hospitals and/or health systems results in increased spending on outpatient prescription drug-based cancer treatment.
An analysis of claims data from the Health Care Cost Institute (HCCI) from 2008 to 2013 finds statistically significant increases in consolidation among outpatient oncology providers and hospitals and/or health systems. These changes largely occurred in 2010 and 2011, according to the recent HCCI report, “The Impact of Provider Consolidation on Outpatient Prescription Drug-based Cancer Care Spending.”
Many policy makers have been concerned about the effects of medical provider consolidation on spending levels and trends because many medical providers have recently merged or affiliated with hospitals or health systems. The effects of such consolidation is ambiguous: it may lead to economies of scale, resulting in reduced spending, or consolidation may allow outpatient practices and/or hospitals to gain bargaining power in negotiations with certain insurers, increasing prices or changing the mix of treatments provided to patients and leading to increased spending. The HCCI report stated that policymakers’ concerns regarding the impact of provider consolidation on outpatient spending are warranted.
Using claims data, the researchers found that increased medical provider consolidation with hospitals and/or health systems results in increased spending on outpatient prescription drug-based cancer treatment. These results appear to be driven in part by increases in the prices charged for treatment, including facility fees that hospital outpatient departments are able to charge payers.
One example cited in the report is that a one percentage point increase in the proportion of medical providers affiliated with hospitals and/or health systems is associated with a 34% increase in average per-person annual spending and a 23% increase in the average per-person price of treatment.
“Comparing the magnitude of the spending and price effects, we believe spending results are in part driven by price increases,” the authors wrote.
More work is needed to understand whether increased spending among vertically concentrated providers is associated with improved quality of care and/or access to care for patients suffering from cancers and insured by commercial payers, state Medicaid programs, and federal Medicare programs. The report notes that it is not known whether these results are generalizable to care consolidation in the outpatient treatment of other specific diseases.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer
April 9th 2025New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with metastatic pancreatic cancer are less likely to receive recommended treatments and achieve longer survival.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen